ArticleInternational journal of clinical and experimental pathology2025
Grossly visible non-invasive neoplasm of the gallbladder: method of classification and its relationship to pyloric gland adenoma.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo devise a classification method for grossly visible non-invasive neoplasms (GVNINs) of the gallbladder and examine their relationship to pyloric gland adenoma (PGA), since clinicopathological features of GVNINs are not well known to date and the relationship between PGA and GVNINs remains unknown.
methodsEighty-five GVNINs were classified into pedunculated (PE), sessile type 1 (SE1), and sessile type 2 (SE2) groups, and into histologic subtypes. Clinicopathologic data, immunohistochemical data surrogating gene abnormalities, and mutational data of CTNNB1, KRAS, and GNAS were obtained. In five cases of SE1 containing PGA-like lesions, separate analyses for PGA-like and non-PGA-like lesions were performed. The relevance of the mucinous tumor cell ratio was analyzed in PE tumors.
resultsThe invasion rates were 0%, 33.4%, and 91.2% for PE, SE1, and SE2, respectively. SE2 was more with ≥ pT2 (78.2%) compared to SE1 (16.7%). All PE and SE1 were of gastric pyloric subtype and gastric type, respectively, whereas pancreatobiliary/intestinal subtypes were predominant in SE2. Approximately 66.7% of SE1 had β-catenin abnormalities, STK11-loss, and CTNNB1 mutation. SMAD4-loss was exclusively seen in the intestinal subtype. Mucinous cell-predominant PGA was not clinicopathologically different from non-mucinous cell-dominant type except for patients' age and nuclear β-catenin labeling index. PGA and PGA-like lesions in SE1 shared β-catenin abnormalities and CTNNB1 mutation, but not STK11-loss.
conclusionsA clinicopathologically relevant classification system for GVNINs was proposed. Histologic subtyping was also important. Non-mucinous cell-predominant PE was suggested to be a similar entity to PGA, while SE1 containing PGA-like lesions were not suggested to be similar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.